person · Reporting owner

Saccomano Nicholas A

Disclosed activity across 2 companies

Tapewire entity: 24488
SEC CIK: 0001609284

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
OnKure Therapeutics, Inc.OKUR · Entity 6550	Director · President and CEO	September 21, 2026	September 23, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

OnKure Therapeutics, Inc.

Report date September 21, 2026 · Filed September 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	11,160	Reported balance After 2026-09-21 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-21 · Sale · Disposed 87 · Balance 11,160 F1: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. F2: This transaction was executed in multiple trades at prices ranging from $2.95 to $3.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2: This transaction was executed in multiple trades at prices ranging from $2.95 to $3.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARRAY BIOPHARMA INC

Report date July 30, 2019 · Filed July 30, 2019

Section 16 reporting ended · disclosed 2019-07-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2019-07-30 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-07-30 · Disposition to issuer · Disposed 150,190 · Balance 61,813 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Row 2 · 2019-07-30 · Disposition to issuer · Disposed 61,813 · Balance 0 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2025-04-01	Direct	Reported balance After 2019-07-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-07-30 · Disposition to issuer · Disposed 165,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F4: The option provided for vesting in four equal annual installments beginning on April 1, 2016.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2026-04-01	Direct	Reported balance After 2019-07-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-07-30 · Disposition to issuer · Disposed 82,500 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F6: The option provided for vesting in four equal annual installments beginning on April 1, 2017.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.79 · Expires 2026-12-27	Direct	Reported balance After 2019-07-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-07-30 · Disposition to issuer · Disposed 131,250 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F7: The option provided for vesting in four equal annual installments beginning on December 26, 2017.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.92 · Expires 2027-12-16	Direct	Reported balance After 2019-07-30 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-07-30 · Disposition to issuer · Disposed 168,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F8: The option provided for vesting in four equal annual installments beginning on December 16, 2018.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.97 · Expires 2028-12-16	Direct	Reported balance After 2019-07-30 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-07-30 · Disposition to issuer · Disposed 138,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F9: The option provided for vesting in four equal annual installments beginning on December 16, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.

F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.

F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.

F4: The option provided for vesting in four equal annual installments beginning on April 1, 2016.

F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.

F6: The option provided for vesting in four equal annual installments beginning on April 1, 2017.

F7: The option provided for vesting in four equal annual installments beginning on December 26, 2017.

F8: The option provided for vesting in four equal annual installments beginning on December 16, 2018.

F9: The option provided for vesting in four equal annual installments beginning on December 16, 2019.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 21, 2026 Filed Sep 23, 2026 20:54 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	SaleClass A Common Stock	87	$2.97	$258.76	Disclosure SEC source: 0001609284-26-000005 · form4-09232026_080903.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,160 F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.95 to $3.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document
August 07, 2026 Filed Aug 11, 2026 20:27 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantEmployee Stock Option (right to buy) · Derivative	542,232	Not disclosed Strike: $4.14	Not disclosed	Disclosure SEC source: 0001609284-26-000004 · form4-08112026_080840.xml · derivative · entry 11 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 542,232 Underlying: Class A Common Stock · 542,232 shares Expires 2034-10-03 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F6 · derivative.exercise_date: 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
August 07, 2026 Filed Aug 11, 2026 20:27 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	542,232	Not disclosed Strike: $18.20	Not disclosed	Disclosure SEC source: 0001609284-26-000004 · form4-08112026_080840.xml · derivative · entry 10 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 542,232 shares Expires 2034-10-03 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F6 · derivative.exercise_date: 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
August 07, 2026 Filed Aug 11, 2026 20:27 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantEmployee Stock Option (right to buy) · Derivative	16,898	Not disclosed Strike: $4.14	Not disclosed	Disclosure SEC source: 0001609284-26-000004 · form4-08112026_080840.xml · derivative · entry 9 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,898 Underlying: Class A Common Stock · 16,898 shares Expires 2033-10-14 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F2 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
August 07, 2026 Filed Aug 11, 2026 20:27 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	16,898	Not disclosed Strike: $13.99	Not disclosed	Disclosure SEC source: 0001609284-26-000004 · form4-08112026_080840.xml · derivative · entry 8 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 16,898 shares Expires 2033-10-14 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F2 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
August 07, 2026 Filed Aug 11, 2026 20:27 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantEmployee Stock Option (right to buy) · Derivative	8,449	Not disclosed Strike: $4.14	Not disclosed	Disclosure SEC source: 0001609284-26-000004 · form4-08112026_080840.xml · derivative · entry 7 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,449 Underlying: Class A Common Stock · 8,449 shares Expires 2033-10-14 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F2 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
August 07, 2026 Filed Aug 11, 2026 20:27 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	8,449	Not disclosed Strike: $13.99	Not disclosed	Disclosure SEC source: 0001609284-26-000004 · form4-08112026_080840.xml · derivative · entry 6 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 8,449 shares Expires 2033-10-14 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F2 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
August 07, 2026 Filed Aug 11, 2026 20:27 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantEmployee Stock Option (right to buy) · Derivative	1,485	Not disclosed Strike: $4.14	Not disclosed	Disclosure SEC source: 0001609284-26-000004 · form4-08112026_080840.xml · derivative · entry 5 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,485 Underlying: Class A Common Stock · 1,485 shares Expires 2033-08-29 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F5 · derivative.exercise_date: 1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
August 07, 2026 Filed Aug 11, 2026 20:27 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	1,485	Not disclosed Strike: $13.99	Not disclosed	Disclosure SEC source: 0001609284-26-000004 · form4-08112026_080840.xml · derivative · entry 4 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 1,485 shares Expires 2033-08-29 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F5 · derivative.exercise_date: 1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
August 07, 2026 Filed Aug 11, 2026 20:27 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantEmployee Stock Option (right to buy) · Derivative	2,359	Not disclosed Strike: $4.14	Not disclosed	Disclosure SEC source: 0001609284-26-000004 · form4-08112026_080840.xml · derivative · entry 3 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,359 Underlying: Class A Common Stock · 2,359 shares Expires 2032-01-03 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F2 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
August 07, 2026 Filed Aug 11, 2026 20:27 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	2,359	Not disclosed Strike: $21.20	Not disclosed	Disclosure SEC source: 0001609284-26-000004 · form4-08112026_080840.xml · derivative · entry 2 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 2,359 shares Expires 2032-01-10 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F2 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
August 07, 2026 Filed Aug 11, 2026 20:27 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantEmployee Stock Option (right to buy) · Derivative	150,000	$0.00 Strike: $4.14	$0.00	Disclosure SEC source: 0001609284-26-000004 · form4-08112026_080840.xml · derivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Class A Common Stock · 150,000 shares Expires 2036-08-06 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 22, 2026 Filed Jun 24, 2026 23:29 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	SaleClass A Common Stock	86	$4.40	$378.08	Disclosure SEC source: 0001609284-26-000003 · form4-06242026_110612.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,247 F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $4.27 to $4.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. F4 · balance_after: Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026. Read SEC document
April 01, 2026 Filed Apr 3, 2026 19:29 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantEmployee Stock Option (right to buy) · Derivative	330,000	$0.00 Strike: $4.07	$0.00	Disclosure SEC source: 0001609284-26-000002 · form4-04032026_070404.xml · derivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,000 Underlying: Class A Common Stock · 330,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
March 23, 2026 Filed Mar 24, 2026 22:57 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	SaleClass A Common Stock	86	$4.16	$357.46	Disclosure SEC source: 0001609284-26-000001 · form4-03242026_100353.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,333 F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document
December 22, 2025 Filed Dec 24, 2025 01:09 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	SaleClass A Common Stock	87	$2.97	$258.19	Disclosure SEC source: 0001609284-25-000004 · form4-12242025_011243.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,419 F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.82 to $3.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. F4 · balance_after: Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on November 20, 2025. Read SEC document
September 22, 2025 Filed Sep 24, 2025 23:42 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	SaleClass A Common Stock	88	$2.62	$230.87	Disclosure SEC source: 0001609284-25-000003 · form4-09242025_110912.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,506 F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.60 to $2.645. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document
June 23, 2025 Filed Jun 25, 2025 22:52 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	SaleClass A Common Stock	88	$2.38	$209.81	Disclosure SEC source: 0001415889-25-018235 · form4-06252025_100613.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,594 F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.33 to $2.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document
April 07, 2025 Filed Apr 8, 2025 21:32 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	SaleClass A Common Stock	516	$2.67	$1,378.24	Disclosure SEC source: 0001415889-25-010419 · form4-04082025_090410.xml · nonDerivative · entry 2 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,682 F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $2.57 to $3.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document
April 04, 2025 Filed Apr 8, 2025 21:32 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	SaleClass A Common Stock	358	$3.33	$1,191.28	Disclosure SEC source: 0001415889-25-010419 · form4-04082025_090410.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,198 F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.10 to $3.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document
January 27, 2025 Filed Jan 30, 2025 01:36 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantEmployee Stock Option (right to buy) · Derivative	130,000	$0.00 Strike: $5.19	$0.00	Disclosure SEC source: 0001415889-25-002312 · form4-01302025_010119.xml · derivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Class A Common Stock · 130,000 shares Expires 2035-01-26 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
October 04, 2024 Filed Oct 8, 2024 23:29 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantEmployee Stock Option (right to buy) · Derivative	542,232	$0.00 Strike: $18.20	$0.00	Disclosure SEC source: 0001415889-24-024921 · form4-10082024_111041.xml · derivative · entry 6 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 542,232 Underlying: Class A Common Stock · 542,232 shares Expires 2034-10-03 F7 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
October 04, 2024 Filed Oct 8, 2024 23:29 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantEmployee Stock Option (right to buy) · Derivative	8,449	Not disclosed Strike: $13.99	Not disclosed	Disclosure SEC source: 0001415889-24-024921 · form4-10082024_111041.xml · derivative · entry 5 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,449 Underlying: Class A Common Stock · 8,449 shares Expires 2033-10-14 F4 · price: Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share). The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent). F6 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
October 04, 2024 Filed Oct 8, 2024 23:29 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantEmployee Stock Option (right to buy) · Derivative	16,898	Not disclosed Strike: $13.99	Not disclosed	Disclosure SEC source: 0001415889-24-024921 · form4-10082024_111041.xml · derivative · entry 4 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,898 Underlying: Class A Common Stock · 16,898 shares Expires 2033-10-14 F4 · price: Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share). The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent). F6 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
October 04, 2024 Filed Oct 8, 2024 23:29 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantEmployee Stock Option (right to buy) · Derivative	1,485	Not disclosed Strike: $13.99	Not disclosed	Disclosure SEC source: 0001415889-24-024921 · form4-10082024_111041.xml · derivative · entry 3 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,485 Underlying: Class A Common Stock · 1,485 shares Expires 2033-08-29 F4 · price: Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share). The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent). F5 · derivative.exercise_date: 1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
October 04, 2024 Filed Oct 8, 2024 23:29 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantEmployee Stock Option (right to buy) · Derivative	2,359	Not disclosed Strike: $21.20	Not disclosed	Disclosure SEC source: 0001415889-24-024921 · form4-10082024_111041.xml · derivative · entry 2 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,359 Underlying: Class A Common Stock · 2,359 shares Expires 2032-01-10 F4 · price: Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share). The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent). F3 · derivative.exercise_date: 1/12th of the shares subject to the option vested on March 31, 2022 and 1/12th of the shares subject to the option vest on the last day of each quarter thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
October 04, 2024 Filed Oct 8, 2024 23:29 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantClass A Common Stock	4,556	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-024921 · form4-10082024_111041.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,556 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon the meeting of both a "Service-Based Requirement" and a "Liquidity Event Plus Service Requirement." 1/16th of the RSUs met the "Service-Based" requirement on June 20, 2023 and 1/16th of the RSUs are scheduled to meet the Service-Based Requirement on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. The Liquidity Event Plus Service Requirement will be satisfied on the 181st day following the closing of the Merger (as defined below), subject to the Reporting Person continuing as a service provider through such date. On October 4, 2024, the effective time of the Merger, each RSU of OnKure (as defined below) (footnote continued in footnote (2)) F2 · shares: (continued from footnote (1)) was assumed by, and converted into an RSU award of, Reneo (as defined below) covering such number of shares of Reneo Class A Common Stock determined by multiplying the number of shares of OnKure preferred stock subject to the RSU award by a designated exchange ratio (rounded down to the nearest whole share). The Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo Pharmaceuticals, Inc. ("Reneo"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo ("Merger Sub I"), and OnKure, Inc. ("OnKure"), provided for the merger of Merger Sub I with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the "Merger"). After completion of the Merger, the combined company was renamed "OnKure Therapeutics, Inc." and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol "OKUR." F1 · price: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon the meeting of both a "Service-Based Requirement" and a "Liquidity Event Plus Service Requirement." 1/16th of the RSUs met the "Service-Based" requirement on June 20, 2023 and 1/16th of the RSUs are scheduled to meet the Service-Based Requirement on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. The Liquidity Event Plus Service Requirement will be satisfied on the 181st day following the closing of the Merger (as defined below), subject to the Reporting Person continuing as a service provider through such date. On October 4, 2024, the effective time of the Merger, each RSU of OnKure (as defined below) (footnote continued in footnote (2)) F2 · price: (continued from footnote (1)) was assumed by, and converted into an RSU award of, Reneo (as defined below) covering such number of shares of Reneo Class A Common Stock determined by multiplying the number of shares of OnKure preferred stock subject to the RSU award by a designated exchange ratio (rounded down to the nearest whole share). The Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo Pharmaceuticals, Inc. ("Reneo"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo ("Merger Sub I"), and OnKure, Inc. ("OnKure"), provided for the merger of Merger Sub I with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the "Merger"). After completion of the Merger, the combined company was renamed "OnKure Therapeutics, Inc." and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol "OKUR." Read SEC document
July 30, 2019 Filed Jul 30, 2019 20:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Disposition to issuerStock Option (Right to Buy) · Derivative	138,000	Not disclosed Strike: $15.97	Not disclosed	Disclosure SEC source: 0001209191-19-043783 · doc4.xml · derivative · entry 7 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 138,000 shares Expires 2028-12-16 F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F9 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on December 16, 2019. Read SEC document
July 30, 2019 Filed Jul 30, 2019 20:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Disposition to issuerStock Option (Right to Buy) · Derivative	168,000	Not disclosed Strike: $10.92	Not disclosed	Disclosure SEC source: 0001209191-19-043783 · doc4.xml · derivative · entry 6 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 168,000 shares Expires 2027-12-16 F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F8 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on December 16, 2018. Read SEC document
July 30, 2019 Filed Jul 30, 2019 20:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Disposition to issuerStock Option (Right to Buy) · Derivative	131,250	Not disclosed Strike: $8.79	Not disclosed	Disclosure SEC source: 0001209191-19-043783 · doc4.xml · derivative · entry 5 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 131,250 shares Expires 2026-12-27 F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F7 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on December 26, 2017. Read SEC document
July 30, 2019 Filed Jul 30, 2019 20:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Disposition to issuerStock Option (Right to Buy) · Derivative	82,500	Not disclosed Strike: $3.00	Not disclosed	Disclosure SEC source: 0001209191-19-043783 · doc4.xml · derivative · entry 4 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82,500 shares Expires 2026-04-01 F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F6 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on April 1, 2017. Read SEC document
July 30, 2019 Filed Jul 30, 2019 20:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Disposition to issuerStock Option (Right to Buy) · Derivative	165,000	Not disclosed Strike: $7.30	Not disclosed	Disclosure SEC source: 0001209191-19-043783 · doc4.xml · derivative · entry 3 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 165,000 shares Expires 2025-04-01 F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F4 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on April 1, 2016. Read SEC document
July 30, 2019 Filed Jul 30, 2019 20:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Disposition to issuerCommon Stock	61,813	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-043783 · doc4.xml · nonDerivative · entry 2 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2 · kind: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3 · price: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU. Read SEC document
July 30, 2019 Filed Jul 30, 2019 20:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Disposition to issuerCommon Stock	150,190	$48.00	$7,209,120.00	Disclosure SEC source: 0001209191-19-043783 · doc4.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,813 F1 · kind: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2 · kind: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Read SEC document
April 01, 2019 Filed Apr 3, 2019 16:30 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	6,875	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-19-002182 · primarydocument.xml · derivative · entry 4 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,875 Underlying: Common Stock · 6,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The RSUs vest and will be settled in stock in four equal annual installments beginning April 1, 2016. F4 · derivative.expiration_date: The RSUs vest and will be settled in stock in four equal annual installments beginning April 1, 2016. Read SEC document
April 01, 2019 Filed Apr 3, 2019 16:30 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	6,875	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-19-002182 · primarydocument.xml · derivative · entry 3 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The RSUs vested and settled in stock in four equal annual installments beginning April 1, 2015. F3 · derivative.expiration_date: The RSUs vested and settled in stock in four equal annual installments beginning April 1, 2015. Read SEC document
April 01, 2019 Filed Apr 3, 2019 16:30 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Tax withholdingCommon Stock	6,048	$24.60	$148,780.80	Disclosure SEC source: 0001562180-19-002182 · primarydocument.xml · nonDerivative · entry 2 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,190 F2 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document
April 01, 2019 Filed Apr 3, 2019 16:30 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	13,750	$0.00	$0.00	Disclosure SEC source: 0001562180-19-002182 · primarydocument.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted on April 1, 2015 and April 1, 2016, as a result of the vesting of one fourth of such RSUs. Read SEC document
February 07, 2019 Filed Feb 8, 2019 18:32 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	82,500	$0.00 Strike: $3.00	$0.00	Disclosure SEC source: 0001562180-19-000860 · primarydocument.xml · derivative · entry 5 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2026-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in four equal annual installments beginning on April 1, 2017. Read SEC document
February 07, 2019 Filed Feb 8, 2019 18:32 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	104,764	$0.00 Strike: $4.20	$0.00	Disclosure SEC source: 0001562180-19-000860 · primarydocument.xml · derivative · entry 4 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 104,764 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal annual installments beginning May 30, 2015. Read SEC document
February 07, 2019 Filed Feb 8, 2019 18:32 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	187,264	$21.58	$4,041,756.36	Disclosure SEC source: 0001562180-19-000860 · primarydocument.xml · nonDerivative · entry 3 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,488 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $21.50 to $21.785. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
February 07, 2019 Filed Feb 8, 2019 18:32 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	104,764	$4.20	$440,008.80	Disclosure SEC source: 0001562180-19-000860 · primarydocument.xml · nonDerivative · entry 2 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 07, 2019 Filed Feb 8, 2019 18:32 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	82,500	$3.00	$247,500.00	Disclosure SEC source: 0001562180-19-000860 · primarydocument.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 31, 2019 Filed Feb 4, 2019 16:28 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	95,236	$0.00 Strike: $4.20	$0.00	Disclosure SEC source: 0001562180-19-000727 · primarydocument.xml · derivative · entry 3 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,764 Underlying: Common Stock · 95,236 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in four equal annual installments beginning May 30, 2015. Read SEC document
January 31, 2019 Filed Feb 4, 2019 16:28 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Tax withholdingCommon Stock	21,425	$18.67	$400,004.75	Disclosure SEC source: 0001562180-19-000727 · primarydocument.xml · nonDerivative · entry 2 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,488 F1 · price: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document
January 31, 2019 Filed Feb 4, 2019 16:28 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	95,236	$4.20	$399,991.20	Disclosure SEC source: 0001562180-19-000727 · primarydocument.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 16, 2018 Filed Dec 18, 2018 19:49 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	7,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-18-005030 · primarydocument.xml · derivative · entry 6 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 7,000 shares Expires 2021-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The RSUs vested and were settled in common stock on December 16, 2018. Read SEC document
December 16, 2018 Filed Dec 18, 2018 19:49 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	5,469	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-18-005030 · primarydocument.xml · derivative · entry 5 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,938 Underlying: Common Stock · 5,469 shares Expires 2020-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The RSUs vested and were settled in common stock on December 16, 2018. Read SEC document
December 16, 2018 Filed Dec 18, 2018 19:49 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Tax withholdingCommon Stock	5,485	$15.97	$87,595.45	Disclosure SEC source: 0001562180-18-005030 · primarydocument.xml · nonDerivative · entry 2 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,677 F2 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document
December 16, 2018 Filed Dec 18, 2018 19:49 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	12,469	$0.00	$0.00	Disclosure SEC source: 0001562180-18-005030 · primarydocument.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted on December 27, 2016 and December 16, 2017, as a result of the vesting of one fourth of such RSUs. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.